NEW YORK (GenomeWeb) – LifeCodexx and Charité–University Medicine Berlin announced today that they have partnered to develop an assay for the early detection of preeclampsia.

The planned test will be based on LifeCodexx's methylation-specific quantitative PCR technology, which exploits the different methylation profiles of maternal and fetal DNA found in maternal plasma. The company recently received CE marking for a version of its PrenaTest fetal trisomy 21 assay based on the technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.